NYSE:ACH
ACCENDRA HEALTH INC/VA/
Accendia Health Inc offers AI-powered digital therapeutics and behavioral health solutions to hospitals and payers globally.
Key Metrics
Investment Thesis
Bull Case
Accendia Health operates in the high-growth digital therapeutics sector with a first-mover advantage in AI-driven behavioral health solutions that payers are increasingly seeking to reduce costs and improve outcomes. If the company can successfully reverse its revenue decline and stabilize cash flow from operations, the current negative market valuation could present an attractive turnaround opportunity for patient capital investors.
Bear Case
The stock is fundamentally distressed with a net loss of $1.10B, negative shareholders equity of -$461M, and a severe drop in revenue from 2024 to 2025, making it highly speculative. Investors should avoid the stock due to the substantial debt load, including $250M in current long-term debt, combined with operating cash flow outflows that threaten solvency.
About ACCENDRA HEALTH INC/VA/
Accendia Health Inc (ACH) is a global provider of digital therapeutics and AI-driven healthcare solutions, serving hospitals, payers, and providers across North America, Europe, and Asia. The company leverages proprietary software platforms to deliver behavioral health interventions, diabetes management tools, and clinical decision support systems. Key products include Accendia Health's flagship digital therapy platforms integrated into electronic health records.
Analysis
Management Discussion
The company reported a net loss of $1.10 billion for 2025, reflecting continued investment in growth initiatives and potential one-time restructuring charges related to discontinued operations. Despite revenue declining sharply from $10.70B in 2024 to $2.76B in 2025, operating expenses remained high at $1.26B, indicating a disconnect between top-line performance and cost control. Cash flow from operations turned negative at -$358.1M while capital expenditures reached $191.0M, suggesting the company is burning cash rapidly without achieving profitability.
Industry Overview
The digital therapeutics and AI healthcare industry is experiencing rapid expansion as payers shift from fee-for-service to value-based care models requiring cost-effective remote patient monitoring. Regulatory bodies are increasingly endorsing digital health tools for reimbursement, driving demand for validated software solutions like those offered by Accendia Health.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $9.96B | $10.33B | $10.70B | $2.76B |
| Cost of Revenue | $8.13B | $8.21B | $8.48B | $1.47B |
| Gross Profit | $1.83B | $2.13B | $2.22B | $1.29B |
| Operating Expenses | $1.68B | $2.02B | $2.43B | $1.26B |
| Operating Income | $142.9M | $104.5M | $-207.8M | $27.5M |
| R&D | — | $13.2M | $13.0M | — |
| G&A | $1.63B | $1.81B | $1.91B | $1.07B |
| Stock-Based Comp | $21.0M | $23.2M | $26.8M | $12.9M |
| D&A | $228.7M | $287.4M | $264.8M | $214.5M |
| Depreciation | $136.0M | $188.0M | $183.0M | — |
| Amortization | $78.8M | $83.5M | $64.9M | $74.0M |
| Other OpEx | $49.8M | $193.9M | $504.1M | $194.3M |
| Non-Operating Income | $-132.0M | $-159.2M | $-149.6M | $-129.4M |
| Interest Expense | $128.9M | $157.9M | $143.8M | $107.2M |
| Pre-Tax Income | $10.9M | $-54.7M | $-357.4M | $-102.0M |
| Income Tax | $-11.5M | $-13.4M | $5.3M | $729.0K |
| Continuing Ops | $22.4M | $-41.3M | $-362.7M | $-102.7M |
| Discontinued Ops | $0 | $0 | $0 | $-998.0M |
| Net Income | $22.4M | $-41.3M | $-362.7M | $-1.10B |
| Minority Interest | $0 | $0 | $0 | $0 |
| Net to Common | $22.4M | $-41.3M | $-362.7M | $-1.10B |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Current Assets | $2.30B | $2.10B | $2.02B | $547.9M |
| Cash & Equivalents | $69.5M | $243.0M | $49.4M | $282.0M |
| Inventory | $1.33B | $1.11B | $1.13B | $74.4M |
| Other Current Assets | $892.1M | $749.1M | $839.8M | $191.4M |
| Long-Term Assets | $3.09B | $2.99B | $2.64B | $1.90B |
| PP&E (Net) | — | — | — | $256.2M |
| Intangibles | $445.0M | $361.8M | $298.7M | $136.5M |
| Goodwill | $1.64B | $1.64B | $1.33B | $1.23B |
| Operating Leases | $280.7M | $296.5M | $355.6M | $109.1M |
| Other LT Assets | $728.7M | $693.3M | $649.5M | $174.0M |
| Total Assets | $5.39B | $5.09B | $4.66B | $2.45B |
| Current Liabilities | $1.57B | $1.89B | $1.87B | $947.1M |
| Accounts Payable | $1.15B | $1.17B | $1.25B | $363.6M |
| Current Debt | — | $206.9M | $45.5M | $250.0M |
| Current Leases | $76.8M | $85.7M | $91.2M | $43.3M |
| Other Current Liab | $342.2M | $427.4M | $485.0M | $290.2M |
| Long-Term Liabilities | $2.87B | $2.28B | $2.22B | $1.97B |
| LT Operating Leases | $215.5M | $222.4M | $286.2M | $70.3M |
| Other LT Liab | $2.66B | $2.05B | $1.93B | $1.90B |
| Total Liabilities | $4.44B | $4.17B | $4.09B | $2.91B |
| Shareholders' Equity | $945.6M | $924.2M | $565.2M | $-461.0M |
| Retained Earnings | $410.0M | $368.7M | $6.0M | $-1.08B |
| AOCI | $-35.9M | $-31.8M | $-49.3M | $-885.0K |
| Total L&E | $5.39B | $5.09B | $4.66B | $2.45B |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Net Income (CFO) | $22.4M | $-41.3M | $-362.7M | $-1.10B |
| Non-Cash Adjustments | $365.1M | $1.24B | $368.4M | $794.8M |
| Working Capital Changes | $-62.5M | $-460.3M | $155.8M | $-52.3M |
| Cash from Operations | $325.0M | $740.7M | $161.5M | $-358.1M |
| Capital Expenditures | $158.1M | $190.9M | $210.9M | $191.0M |
| Cash from Investing | $-1.80B | $-137.3M | $-116.5M | $144.4M |
| Debt Repayments | $4.5M | $320.7M | $244.2M | — |
| Share Buybacks | — | — | — | $10.2M |
| Dividends Paid | $0 | $0 | — | — |
| Cash from Financing | $1.50B | $-417.3M | $-267.6M | $188.1M |
| FX Effect | $-3.5M | $613.0K | $-901.0K | $1.9M |
| Net Change in Cash | $14.2M | $186.7M | $-223.5M | $232.6M |
| Beginning Cash | $72.0M | $86.2M | $272.9M | $49.4M |
| Ending Cash | $86.2M | $272.9M | $49.4M | $282.0M |
Frequently Asked Questions
How does ACCENDRA HEALTH INC/VA/ make money?
Revenue is derived primarily from software licensing agreements, implementation services for digital therapeutic platforms, and ongoing subscription maintenance fees. The company operates through strategic partnerships with major healthcare systems and payer organizations, focusing on mental health, diabetes care, and chronic disease management verticals.
What are the main risks for ACH?
Significant volatility in cash flow from operations indicates potential liquidity stress or aggressive growth spending that may not yet be profitable. The massive retained earnings deficit and negative shareholders equity suggest substantial accumulated losses that could impact credit ratings or limit future financing options. Heavy reliance on long-term debt with significant current portion creates refinancing risk if market conditions tighten. Regulatory changes in healthcare data privacy or reimbursement policies could materially impact the adoption of digital therapeutics.
What is ACH's competitive advantage?
Accendia Health possesses a robust proprietary AI engine that personalizes patient engagement and improves clinical outcomes, creating high switching costs for enterprise clients. Its extensive network of regulatory approvals and validated clinical data provides a defensible moat in the growing digital therapeutics market. The company's deep integration capabilities with existing Electronic Health Record (EHR) systems reduce implementation friction for large hospital networks.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.